Rathbones Group’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-432,818
| Closed | -$11.3K | – | 647 |
|
|
2025
Q4 | $11.3K | Hold |
432,818
| – | – | ﹤0.01% | 633 |
|
|
2025
Q3 | $56.3K | Hold |
432,818
| – | – | ﹤0.01% | 624 |
|
|
2025
Q2 | $104K | Hold |
432,818
| – | – | ﹤0.01% | 587 |
|
|
2025
Q1 | $85.3K | Hold |
432,818
| – | – | ﹤0.01% | 563 |
|
|
2024
Q4 | $233K | Hold |
432,818
| – | – | ﹤0.01% | 507 |
|
|
2024
Q3 | $411K | Hold |
432,818
| – | – | ﹤0.01% | 437 |
|
|
2024
Q2 | $422K | Hold |
432,818
| – | – | ﹤0.01% | 439 |
|
|
2024
Q1 | $684K | Hold |
432,818
| – | – | ﹤0.01% | 373 |
|
|
2023
Q4 | $343K | Hold |
432,818
| – | – | ﹤0.01% | 455 |
|
|
2023
Q3 | $338K | Hold |
432,818
| – | – | ﹤0.01% | 457 |
|
|
2023
Q2 | $400K | Hold |
432,818
| – | – | ﹤0.01% | 320 |
|
|
2023
Q1 | $472K | Hold |
432,818
| – | – | ﹤0.01% | 304 |
|
|
2022
Q4 | $632K | Hold |
432,818
| – | – | 0.01% | 276 |
|
|
2022
Q3 | $465K | Hold |
432,818
| – | – | 0.01% | 290 |
|
|
2022
Q2 | $736K | Hold |
432,818
| – | – | 0.01% | 265 |
|
|
2022
Q1 | $892K | Hold |
432,818
| – | – | 0.01% | 259 |
|
|
2021
Q4 | $1.62M | Sell |
432,818
-103
| -0% | -$469 | 0.02% | 223 |
|
|
2021
Q3 | $2.24M | Hold |
432,921
| – | – | 0.02% | 198 |
|
|
2021
Q2 | $1.84M | Hold |
432,921
| – | – | 0.02% | 210 |
|
|
2021
Q1 | $2.3M | Hold |
432,921
| – | – | 0.03% | 186 |
|
|
2020
Q4 | $2.33M | Hold |
432,921
| – | – | 0.03% | 181 |
|
|
2020
Q3 | $3.46M | Sell |
432,921
-10,000
| -2% | -$87.5K | 0.06% | 142 |
|
|
2020
Q2 | $4.43M | Buy |
442,921
+44,068
| +11% | +$277K | 0.09% | 119 |
|
|
2020
Q1 | $1.08M | Sell |
398,853
-303,722
| -43% | -$1.01M | 0.03% | 167 |
|
|
2019
Q4 | $843K | Hold |
702,575
| – | – | 0.02% | 202 |
|
|
2019
Q3 | $1.06M | Sell |
702,575
-1,897
| -0.3% | -$4.43K | 0.03% | 187 |
|
|
2019
Q2 | $2.83M | Buy |
704,472
+418,750
| +147% | +$1.71M | 0.09% | 121 |
|
|
2019
Q1 | $1.23M | Buy |
285,722
+62,292
| +28% | +$290K | 0.04% | 163 |
|
|
2018
Q4 | $1.28M | Hold |
223,430
| – | – | 0.05% | 154 |
|
|
2018
Q3 | $3.03M | Sell |
223,430
-20,000
| -8% | -$210K | 0.1% | 110 |
|
|
2018
Q2 | $2.89M | Hold |
243,430
| – | – | 0.11% | 113 |
|
|
2018
Q1 | $2.73M | Sell |
243,430
-69,500
| -22% | -$608K | 0.11% | 114 |
|
|
2017
Q4 | $2.09M | Sell |
312,930
-8,120
| -3% | -$62.7K | 0.09% | 129 |
|
|
2017
Q3 | $2.63M | Buy |
321,050
+120,525
| +60% | +$753K | 0.11% | 118 |
|
|
2017
Q2 | $900K | Hold |
200,525
| – | – | 0.04% | 173 |
|
|
2017
Q1 | $1.1M | Hold |
200,525
| – | – | 0.05% | 156 |
|
|
2016
Q4 | $812K | Sell |
200,525
-129,600
| -39% | -$622K | 0.04% | 168 |
|
|
2016
Q3 | $2.33M | Sell |
330,125
-120,400
| -27% | -$918K | 0.12% | 108 |
|
|
2016
Q2 | $3.67M | Buy |
450,525
+250,000
| +125% | +$2.35M | 0.2% | 84 |
|
|
2016
Q1 | $1.63M | Hold |
200,525
| – | – | 0.1% | 109 |
|
|
2015
Q4 | $1.51M | Buy |
+200,525
| New | +$1.96M | 0.1% | 115 |
|
Other funds holding ADAP
Rathbones Group's ADAP Position: Q1 2026 in Review
Rathbones Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 432,818 shares — an estimated $11.3K sold.
Rathbones Group first reported a position in ADAP in Q4 2015 and held it in 41 quarters. The position peaked at $4.43M in Q2 2020. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.
- Rathbones Group reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
- Rathbones Group sold 432,818 Adaptimmune Therapeutics shares in Q1 2026, an estimated $11.3K.
- Rathbones Group first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 41 quarters.
- Rathbones Group's Adaptimmune Therapeutics position peaked at $4.43M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.
Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.